Cooperation and coordination around children with individual plans

In this article we discuss the relationship between cooperation and coordination around six children with special needs who attend Norwegian day care centres. The children in focus have ‘individual plans’, in which goals, roles and activities at the centre of the cooperation are documented, and are as such a coordinating device. Each child has a cooperative team consisting of parents, representatives from day care centre, the child's special educator, the public health nurse and, for instance, their physiotherapist, family doctor etc. to support them. The cooperating teams are headed by a coordinator, who in most cases is the public health nurse. Methods used in the study are individual interviews with at least four representatives from each cooperative team, as well as two focus group interviews with representatives from two different specialist units. The research design is action oriented, and involves, in addition to data collection, two seminars with parents and practitioners from the day care centre and social/health sectors. Departing from the empirical findings in the project we discuss how the coordinating practices, such as the individual plan and the designation of coordinators, influence the cooperation in the teams around each child. Our findings indicate that cooperation benefits from a bottom-up process, in which it is the cooperation that structures the coordination, rather than vice versa

Opplæring gitt i forbindelse med implementeringen av kvalifiseringsprogrammet ved NAV-kontorene

Evalueringen omhandler en opplæring i AI (Appreciative Inquiry) gitt til såkalte prosessveiledere i forbindelse med implementeringen av Kvalifiseringsprogrammet. Prosessveilederne er meget tilfredse med opplæringen, og AI-tilnærmingen anses som nyttig og relevant. De aller fleste har bukt verktøyene fra opplæringen. Det er imidlertid en del forhold, hovedsakelig av organisatorisk art, som bidrar til at prosessveiledernes kompetanse i liten grad blir nyttiggjort og ”tilbudt” mottakerne

Boligsosialt utviklingsprogram i Moss kommune - en foranalyse

Agderforskning har på oppdrag fra Moss kommune gjennomført en foranalyse av det boligsosiale arbeidet i Moss og innhentet og sammenliknet enkelte nøkkeldata som beskriver situasjonen.Foranalysen er initiert av kommunens deltakelse i Husbankens boligsosiale utviklingsprogram,som pågår fram til mai 2014. Våre analyser og vurderinger er gjort med utgangspunkt i følgende: - Intervjuer med nøkkelpersone på rådmanns/enhetslederniv i Moss, Rygge, Råde og Våler - Et fellesmøte med nøkkelpersoner fra Moss kommune og brukerrepresentanter - Tilgjengelig statistikk og data - Relevante nasjonale og kommunale styringsdokumenter, NOU-er og annen relevant forskningslitteratu

First results from the L3+C experiment at CERN

The L3+C experiment combines the high-precision spectrometer of the L3 detector at LEP, CERN, with a small air shower array. The momenta of cosmic ray induced muons can be measured from 20 to 2000 GeV/c. During the 1999 data taking period 5 billion muon events were recorded in the spectrometer. From April until mid Summer 2000 an additional 3 billion muon events have been recorded as well as 25 million air shower events. Here the first results on the muon momentum spectrum and charge ratio will be presented

Status for miljøet i norske havområder - Rapport fra Overvåkingsgruppen 2023

I denne rapporten gir Overvåkingsgruppen, for første gang, en felles vurdering av miljøtilstanden i Barentshavet og havområdene utenfor Lofoten, Norskehavet og Nordsjøen med Skagerrak. Det er også første rapport som bruker resultater fra det nylig utviklede fagsystemet for vurdering av økologisk tilstand. I denne rapporten dekkes to hovedtemaer: (1) Dominerende trekk i status og utvikling i økosystemet i alle tre havområdene, basert på vurderingene av økologisk tilstand, Overvåkingsgruppens rapport om forurensning fra 2022, indikatorer fra Overvåkingsgruppen som ikke er dekket under vurdering av økologisk tilstand, samt rapporter og annen relevant informasjon fra forskning, og (2) en vurdering av karbonbinding i marint plankton, marine vegetasjonstyper og marine sedimenter. I tillegg er det gitt en oppsummering for endringer i ytre påvirkning, vurdering av kunnskapsbehov samt en vurdering av indikatorverdier i forhold til referanseverdier og tiltaksgrenser. Vurderingen av dominerende trekk i utvikling og tilstand av miljøet som er gitt i kapittel 2, utgjør Overvåkingsgruppens bidrag til Faglig forums samlerapport om det faglige grunnlaget for revisjon og oppdatering av de helhetlige forvaltningsplanene for norske havområder.Status for miljøet i norske havområder - Rapport fra Overvåkingsgruppen 2023publishedVersio

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.

To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified nine new susceptibility loci for different EOC histotypes: six for serous EOC histotypes (3q28, 4q32.3, 8q21.11, 10q24.33, 18q11.2 and 22q12.1), two for mucinous EOC (3q22.3 and 9q31.1) and one for endometrioid EOC (5q12.3). We then performed meta-analysis on the results for high-grade serous ovarian cancer with the results from analysis of 31,448 BRCA1 and BRCA2 mutation carriers, including 3,887 mutation carriers with EOC. This identified three additional susceptibility loci at 2q13, 8q24.1 and 12q24.31. Integrated analyses of genes and regulatory biofeatures at each locus predicted candidate susceptibility genes, including OBFC1, a new candidate susceptibility gene for low-grade and borderline serous EOC

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Recurrent, Activating Variants in the Receptor Tyrosine Kinase <i>DDR2</i> Cause Warburg-Cinotti Syndrome

We have investigated a distinct disorder with progressive corneal neovascularization, keloid formation, chronic skin ulcers, wasting of subcutaneous tissue, flexion contractures of the fingers, and acro-osteolysis. In six affected individuals from four families, we found one of two recurrent variants in discoidin domain receptor tyrosine kinase 2 (DDR2): c.1829T&gt;C (p.Leu610Pro) or c.2219A&gt;G (p.Tyr740Cys). DDR2 encodes a collagen-responsive receptor tyrosine kinase that regulates connective-tissue formation. In three of the families, affected individuals comprise singleton adult individuals, and parental samples were not available for verification of the de novo occurrence of the DDR2 variants. In the fourth family, a mother and two of her children were affected, and the c.2219A&gt;G missense variant was proven to be de novo in the mother. Phosphorylation of DDR2 was increased in fibroblasts from affected individuals, suggesting reduced receptor autoinhibition and ligand-independent kinase activation. Evidence for activation of other growth-regulatory&nbsp;signaling pathways was not found. Finally, we found that the protein kinase inhibitor dasatinib prevented DDR2 autophosphorylation in fibroblasts, suggesting an approach to treatment. We propose this progressive, fibrotic condition should be designated as Warburg-Cinotti syndrome